Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results.
Secretome Therapeutics says it will present Phase 1 safety/tolerability data for STM-01 in HFpEF at HFSA on Oct. 11, 2026, including results from 10 patients with no treatment-related TEAEs and generally favorable exploratory trends.
Secretome Therapeutics said clinical data from its Phase 1 study of STM-01 in heart failure with preserved ejection fraction will be presented at the HFSA Annual Scientific Meeting.